ArticleMolecular imaging and biology2017
A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- A tissue-informed deep learning-based method for positron range correction in preclinical [Formula: see text]Ga PET imaging.EJNMMI physics · 2026Article
- First positronium lifetime imaging usingScientific reports · 2026Article
- Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.Molecules (Basel, Switzerland) · 2025Article
- Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals.Angewandte Chemie (International ed. in English) · 2024Article
- Inductively Coupled Plasma-Mass Spectrometry (ICP-MS): An Emerging Tool in Radiopharmaceutical Science.Journal of the American Chemical Society · 2024Review
- Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [Bioconjugate chemistry · 2024Article
- Radiochemistry: A Hot Field with Opportunities for Cool Chemistry.ACS central science · 2023Review
- Preclinical evaluation of [Scientific reports · 2023Article
- Separation of cyclotron-produced cobalt-55/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2023Article
- Yields of Photo-Proton Reactions on Nuclei of Nickel and Separation of Cobalt Isotopes from Irradiated Targets.Molecules (Basel, Switzerland) · 2022Article
- Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.Theranostics · 2022Article
- Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) comprises a recognized target for molecular imaging of prostate cancer. As such, radiolabeled PSMA inhibitors are of great value for diagnosis and staging of this disease. Herein, we disclose the preclinical characterization of [ PROCEDURES: By the application of microwave heating, PSMA-617 in acetate buffer (0.4 M, pH 4.4) was labeled with the radioisotopes cobalt-55/57. The extents of internalization and dissociation constants (K
resultsThe radiolabeling with cobalt-55/57 was performed in yields greater than 99.5 and 99.8 % and radiochemical purities of 99.7 and 98.9 %, respectively. The molar-specific activities were 18.2 MBq/nmol and 3.3 MBq/nmol. The cellular K
conclusionRadiolabeling of PSMA-617 was achieved in excellent yields and radiochemical purities. Favorable in vitro data comprising low K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.